1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of the American College of Cardiology

• Publication date

  2016-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2016.05.078PMID 27515333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients

  2016cited by this paper
• Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint

  2016cited by this paper
• 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa

  2016cited by this paper
• Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe.

  2016cited by this paper
• Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.

  2016cited by this paper
• What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention?

  2015cited by this paper
• 2014 ESC/EACTS guidelines on myocardial revascularization.

  2015cited by this paper
• Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction

  2015cited by this paper
• Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2015cited by this paper
• Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: a meta-regression analysis of 30 randomized trials.

  2014cited by this paper
• Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome.

  2014cited by this paper
• ESC / EACTS Guidelines on myocardial revascularization

  2014cited by this paper
• Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction.

  2014cited by this paper
• Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial.

  2014cited by this paper
• Outcomes 1 year after thrombus aspiration for myocardial infarction.

  2014cited by this paper
• Changes in diabetes-related complications in the United States.

  2014cited by this paper
• Changes in diabetes-related complications in the United States, 1990-2010.

  2014cited by this paper
• Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.

  2014influential reference
• 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

  2014cited by this paper
• Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent

  2013cited by this paper
• Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction: One-Year Results From the INFUSE-AMI Trial

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.

  2013cited by this paper
• Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

  2012cited by this paper
• Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year

  2011cited by this paper
• Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis

  2011cited by this paper
• Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction

  2011cited by this paper
• Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction

  2010cited by this paper
• Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction.

  2010cited by this paper
• Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

  2010cited by this paper
• Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.

  2009cited by this paper
• Diabetes and mortality following acute coronary syndromes.

  2007cited by this paper
• Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

  2000cited by this paper
• Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi

  year unknowncited by this paper

• Therapeutic potential of integrins in diabetic retinopathy

  2025cites this paper
• Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)

  2022cites this paper
• NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: insight from the On-Time II trial.

  2020cites this paper
• Big Health Data and Cardiovascular Diseases: A Challenge for Research, an Opportunity for Clinical Care

  2019cites this paper
• Pre‐hospital administration of ticagrelor in diabetic patients with ST‐elevation myocardial infarction undergoing primary angioplasty: A sub‐analysis of the ATLANTIC trial

  2018cites this paper
• Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention

  2017cites this paper
• Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives

  2017cites this paper
• Intracoronary Abciximab in Diabetic STEMI Patients: Questionable Benefit, Proven Harm.

  2016cites this paper
• World Journal of Diabetes

  year unknowncites this paper
• Intracoronary Abciximab in Diabetic STEMI Patients Questionable Bene fi t, Proven Harm*

  year unknowninfluential citation